Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
The dozens of x10 trades are placed via SETs and tend to be part of larger trades with identical trade times eg. 4990 +10.
Imho just computers doing what they’re programmed to do. Nothing significant.
;-)
Would like to see some market share data to see how they’ve done against John Lewis since the latter’s collapse.
I recall that in a very fragmented market, JL were mkt leaders with about 10% then Dunelm and a load of independents who were getting mopped up.
Could be a case of ‘last man standing’?
‘....we expect to end the year modestly ahead of the top of the current range of analyst expectations’.
Decent performance imho given stores were closed.
It obviously still grates that other rival stores were classed as ‘essential’.
And giveaway by our ‘friends at Link....
https://www.thetimes.co.uk/article/top-biotech-s-2bn-float-boosts-city-zkdc58jf2?shareToken=086e75640862e1b429b339a4adbb71f7
BarryBrownPees,
Probably not on the molecule. But there’ll be a patent on the delivery system ie inhaler, spinhaler, turbohaler etc
But the asthma ‘population’ is pretty well known, whereas the Covid + future endemics could be vast.
Skippysb01,
Yup, I get all that. But you could use that argument about many drugs used in the community setting eg anti-asthma inhalers, which if not used may result in the patient ending up in an ambulance on their way to A&E. Yet they cost about £20 for 200 doses.
Also the ethos behind the ‘amazingly successful’ Recovery Trial is ‘cheap and cheerful’ re-purposing of existing therapy, costing a few £££s.
This is just from a UK perspective and other markets are different. Each country has its own healthcare system, which makes drug pricing complex(which is why we have so-called Parallel Imports).
Anyway- this is all academic.
Fingers crossed for a +ve HT and phase III.
;-)
‘...IFN test says you have a poor IFN response, Full at home SNG kit is sent and contact from the 'at home' nurse.’
This could well be the scenario.
But, sorry, imho there’s NO WAY you could charge £2k per treatment under those circumstances.
2 X 342k ‘Buys’ went through at £21.97 this pm. But had no effect and haven’t shown up here.
Odd?
It seems odd to me that the sp can drop so (relatively) far on such repeated small daily volumes(less than 0.5% ) without some +ve response.
So 99% of holders are ‘comfortable’ with their position and reluctant to increase at prices now well below the ‘over-subscribed’ Placing at 175p. That’s weird. Unless it is to do with ISA/Tax planning with CGT already a ‘problem’?
Anyway, LTHs will be familiar with this drop-off, which reached a peak/trough just prior to the good news last July.
So, fingers crossed.
Recent volumes traded each day in SNG struggle to reach 1% of shares in issue, so it’s fair to say that the vast majority of holders (and hence their stock) are indeed remaining patient, waiting for a hint of news.
MasterRSI,
Volumes are so low at the moment-less than 1% recently- that it must be easy to set up a BOT via SETs to churn the shares to gain 1p here and there.
‘Sells’ at low 160s and 150s must be at a loss, but the absence of any buyers in volume has led to the current impasse, imho.
Even the late reported trades have virtually dried up.
So we wait....